Voxelotor (GBT440) in pediatric sickle cell disease: A review
Sickle cell disease (SCD) was first described in 1910 in African Americans, and the mutant hemoglobin S (HbS) was identified by electrophoresis in 1948. Sickle cell disease is the first genetic disease to be molecularly defined - a single point mutation in the β-globin gene (GAG→GTG) results in subs...
Saved in:
Main Authors: | Sri Lakshmi Jamalapur (Author), Alexander K. Glaros (Author), Yaddanapudi Ravindranath (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
by: Michael Migotsky, et al.
Published: (2022) -
Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma
by: Radojka M. Savic, et al.
Published: (2022) -
Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action
by: Michelle L. Green, et al.
Published: (2022) -
More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
by: Paul Langley
Published: (2020) -
Retrospective analysis of drug eruption in 440 cases
by: Wei LI, et al.
Published: (2020)